Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

Launched by NOVO NORDISK A/S · Aug 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called turoctocog alfa for patients with Haemophilia A, a condition that affects the blood's ability to clot and can lead to excessive bleeding. The goal of the study is to understand how this treatment is used in everyday practice by looking at the medical records of male patients who have switched from a previous therapy to turoctocog alfa. This means that participants will not receive any new treatments or changes in their care; instead, the study will gather information about their health and treatment history to help improve future care for people with Haemophilia A.

To be eligible for the trial, participants must be male, either children or adults, who have already been treated for Haemophilia A with other therapies. The study includes patients who need treatment on-demand (only when they have a bleeding episode) or those who are on regular preventive treatment. However, patients with other bleeding disorders, like Von Willebrand disease, or those who have developed specific antibodies against the treatment, will not be included. If eligible, participants can expect their existing medical records to be reviewed and used to help better understand the use of turoctocog alfa in managing their condition.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Paediatric and adult male patients
• • On-demand and prophylactic patients with haemophilia A (any severity)
• • Only previously treated patients (previous FVIII replacement therapy) will be included in the study
• Exclusion Criteria:
• • Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease
• • Patients with documented presence of any FVIII inhibitor